Search research articles
Contact Us
Filters
Showing results (31-40 of 88) with videos related to
Page
of 9
Sort By:
Genome Biology
|
September 28, 2014
Dynamic evolution of clonal epialleles revealed by methclone
Sheng Li, Francine Garrett-Bakelman, Alexander E Perl, et al.
Leukemia Research
|
March 27, 2026
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025
Hetty E Carraway, Daniel J DeAngelo, Eunice S Wang, et al.
Blood
|
October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K Tasian, David T Teachey, Yong Li, et al.
Transplantation and Cellular Therapy
|
August 2, 2021
Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation
Craig W Freyer, Michael Fradley, David Madnick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Blood Advances
|
April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First
Mark J Levis, Harry P Erba, Pau Montesinos, et al.
Blood
|
May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Investigational New Drugs
|
April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
Margaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.
Nature
|
April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 88) with videos related to
Sort By:
Page
of 9
Genome Biology
|
September 28, 2014
Dynamic evolution of clonal epialleles revealed by methclone
Sheng Li, Francine Garrett-Bakelman, Alexander E Perl, et al.
Leukemia Research
|
March 27, 2026
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025
Hetty E Carraway, Daniel J DeAngelo, Eunice S Wang, et al.
Blood
|
October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K Tasian, David T Teachey, Yong Li, et al.
Transplantation and Cellular Therapy
|
August 2, 2021
Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation
Craig W Freyer, Michael Fradley, David Madnick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Blood Advances
|
April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First
Mark J Levis, Harry P Erba, Pau Montesinos, et al.
Blood
|
May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Investigational New Drugs
|
April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
Margaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.
Nature
|
April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
Page
of 9